Rhogam Related Published Studies
Well-designed clinical trials related to Rhogam (IgG Anti-D)
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. [2008.03]
Kinetics of the immune response following pneumococcal PD conjugate vaccination. [2007.03.01]
Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. [2003.01]
Well-designed clinical trials possibly related to Rhogam (IgG Anti-D)
Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. [2008.12]
A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children. [2008.08]
Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. [2008.07]
Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. [2008.04]
Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. [2008.02]
Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. [2007.12.11]
Malaria incidence and efficacy of intermittent preventive treatment in infants (IPTi). [2007.12.09]
The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies. [2007.10]
Antepartum Treatment Without Early Cordocentesis for Standard-Risk Alloimmune Thrombocytopenia: A Randomized Controlled Trial. [2007.08]
Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. [2007.05]
THROMBOCYTOPENIA ASSOCIATED WITH DENGUE HEMORRHAGIC FEVER RESPONDS TO INTRAVENOUS ADMINISTRATION OF ANTI-D (RH0-D) IMMUNE GLOBULIN. [2007.04]
Prospective evaluation of high-cost management of severe chronic ITP in children and adolescents<16 years. [2006.10.15]
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. [2006.04]
Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. [2006]
Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. [2004.12.01]
Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. [2004.04]
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. [2004.04]
Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. [2002.03]
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. [2001.03]
High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. [1995.07]
Multicentre trial of antepartum low-dose anti-D immunoglobulin. [1995.03]
The use of anti-D to improve post-transfusion platelet response: a randomized trial. [1995.01]
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. [1994.09.10]
Other research related to Rhogam (IgG Anti-D)
IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? [2007.10]
Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells. [2007.01]
Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight. [2004.04]
Variable inhibition of placental IgG transfer in vitro with commercial IVgG preparations. [1999.12]
Evaluation by enzyme-linked immunosorbent assay of IgG anti-D and IgG subclass concentrations in immunoglobulin preparations. [1999.05]
Are there options for donor-derived i.m. anti-D IgG preparations other than to prevent Rh(D) sensitization? The intravenous route. [1995.12]
Quantification of IgG anti-D bound to D-positive red cells infused into D-negative subjects after intramuscular injection of monoclonal anti-D. [1995.06]
In vitro production of interleukin-1 receptor antagonist in IgG-mediated red cell incompatibility. [1994.04]
Cytokine production in IgG-mediated red cell incompatibility. [1993.01]
[Rhesus(D)-IgG-antibodies in the treatment of autoimmune thrombocytopenia] [1992.01.03]
[Use of anti-D (Rh) IgG or intramuscular polyvalent human immunoglobulin in the treatment of chronic autoimmune thrombocytopenic purpura] [1992]
High-dose intravenous IgG for the treatment of severe rhesus alloimmunization. [1991]
A vascular effect of IgG therapy may prevent transplacental red cell leakage and spontaneous thrombocytopenic haemorrhages. [1990.11]
Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. [1990.10]
The successful treatment of idiopathic thrombocytopenic purpura with the low dose non specific IgG component of anti D immunoglobulin. [1990]
Other possibly related research studies
The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. [2006.01]
The issue of anti-D: an integrated seamless approach from recognition of need to bedside administration. [2005.07]
Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*. [2005.11]
[Evaluation of fetomaternal hemorrhage in postpartum patients with indication for administration of anti-D immunoglobulin] [2005.09]
Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. [2005.10]
Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. [2005.08]
Evaluation of 2-column agglutination versus conventional tube technique for antibody screening. [2003.05]
Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. [2005.03]
Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. [2005.03]
[The effect of opsonins on erythrocytes' phagocytosis in the vitreous--clinical observations (Part B)] [2004]
Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin. [2004.12]
Kleihauer-betke testing is important in all cases of maternal trauma. [2004.11]
Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. [2004.11]
Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. [2004.10]
The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. [2004.09]
Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. [2004.07]
Isoimmunization in pregnancy. [2004.06]
Management of immune thrombocytopenic purpura in adults. [2004.04]
After eight-year-tolerance minimal i.v. anti-D infusions unleash hemolysis in a patient with immune thrombocytopenic purpura (ITP). [2004.04]
Three cases of massive fetomaternal hemorrhage presenting without clinical suspicion. [2004.04]
Collaborative study for establishment of a global standard for the potency assay of human anti-D immunoglobulin. [2004.01]
Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. [2004.01]
Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura. [2003.11]
False positive Kleihauer tests and unnecessary administration of anti-D immunoglobulin. [2003.12]
Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. [2003.12]
A global standard for anti-D immunoglobulin: international collaborative study to evaluate a candidate preparation. [2003.11]
Rh negative status and isoimmunization update: a case-based approach to care. [2003.07]
Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. [2003.10.15]
Is the incidence of fetal-to-maternal hemorrhage increased in patients with third-trimester bleeding? [2003.06]
Prevalence of D(u) phenotype amongst rhesus negative females in Port Harcourt, Nigeria. [2003.04]
An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside. [2001.05]
Is Rh immune globulin needed in early first-trimester abortion? A review. [2003.03]
Lack of anti-D in women at birth following antepartum immune globulin prophylaxis. [2003.03.26]
Fetal-maternal hemorrhage detection in Ontario. [2003.01]
[Maternal complications of fetal hydrops] [2002.12.07]
Non-evidence-based use of Rho(D) immune globulin for threatened abortion by family practice and obstetric faculty physicians. [2002.11]
Treatment requirements of infants with rhesus isoimmunisation within a geographically defined area. [2002.11]
Perinatal immunomodulation. [2002.05]
Incidence of Rhesus isoimmunization in Rhesus-negative mothers in Ramadi, Iraq, in the mid-1990s. [2000.09]
Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura. [2002.09]
Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. [2002.08]
[Foetal-maternal alloimmunizations in the South-East area of the Venice province] [2002.08]
Reported management of early-pregnancy bleeding and miscarriage by general practitioners in Victoria. [2002.01.21]
Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia. [2001.10]
Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. [2002.02]
Lack of association between hepatitis C viral RNA in serum and liver and histologic gradings: a study on Irish anti-D-treated patients. [2002.03]
Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency. [2002.01]
[Immune cytopenias in newborns] [2001.09.15]
RhD isoimmunization and current management modalities. [2001.11]
Management of immune thrombocytopenic purpura in children. [2001.09]
Use of anti-D immunoglobulin in the treatment of threatened miscarriage in the accident and emergency department. [2001.11]
Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. [2001.11]
Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content. [2001.06]
The frequency of anti-C + anti-G in the absence of anti-D in alloimmunized pregnancies. [2001.06]
Rhesus isoimmunization. [2001.05]
Detection of massive transplacental haemorrhage by flow cytometry. [2000.12]
Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy? [2001.05]
The first example of a paraben-dependent antibody to an Rh protein. [2001.03]
Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. [2001.01]
Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? [2000.12]
|